Physician profile
Son G Lam
NPI 1407866650
$6,432.88
in general payments reported to CMS, 2019-2025
26 companies · $956 in 2025
The $956 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $398 · 2021: $705 · 2022: $1,282 · 2023: $1,390 · 2024: $1,227 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.10 |
| Education | $222.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,033.90 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $757.37 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $715.39 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $490.44 | 2019-2025 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $434.64 | 2019-2023 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $359.76 | 2021-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $337.24 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $328.22 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $314.96 | 2020-2024 | Rayaldee |
| Amgen INC. | $273.25 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Glaxosmithkline, LLC. | $187.98 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Fresenius USA Marketing, INC. | $180.57 | 2019-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $172.87 | 2019-2025 | Injectafer |
| Ani Pharmaceuticals, INC. | $153.22 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $145.83 | 2021-2024 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.40 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $88.75 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $70.58 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $69.90 | 2021 | |
| Novo Nordisk INC | $48.25 | 2025 | Ozempic |
| Mallinckrodt Enterprises LLC | $42.61 | 2019 | |
| Apellis Pharmaceuticals, INC. | $37.28 | 2025 | |
| Renalytix Ai, INC. | $23.99 | 2022 | |
| Genentech USA, INC. | $21.34 | 2019 | |
| La Jolla Pharmaceutical Company | $19.26 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.